NCT04954911 (GLOBE-EU) is a clinical trial in Atrial Fibrillation, sponsored by Kardium Inc..

Who is sponsoring NCT04954911?

NCT04954911 is sponsored by Kardium Inc..

What condition does NCT04954911 study?

NCT04954911 studies Atrial Fibrillation.

Is NCT04954911 still recruiting?

NCT04954911 is currently completed. Last updated 18 September 2023.

Last reviewed 2023-09-18 · How we verify

NCT04954911: GLOBE-EU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Performance of the Globe® Mapping and Ablation System for the Treatment of Atrial Fibrillation

Completed Last updated 18 September 2023

What this trial tests

trial in Atrial Fibrillation in 6 participants. Completed in 23 May 2023.

Timeline

2 November 2021

Primary endpoint
23 May 2023

23 May 2023

Quick facts

Lead sponsor	Kardium Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6
Start date	2 November 2021
Primary completion	23 May 2023
Estimated completion	23 May 2023
Sites	2 locations across Germany

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Kardium Inc.

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, multicentre, prospective, post-market product registry for participants with AF for whom ablation by the commercially available Globe Mapping and Ablation System was indicated before enrolment into the registry. The aim of the registry is to confirm the clinical performance and safety of the Globe Mapping and Ablation System in a real-life setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Kardium Inc. trials

Trials by the same sponsor.

NCT04486924 — Performance and Safety of the Globe® Mapping and Ablation System With the GPS™ Module for the Treatment of Atrial Fibril · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04954911 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kardium Inc.
Last refreshed: 18 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04954911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing